Roche plans to invest over 100 million Swiss francs in Kaiseraugst
Basel, 16 July 2013
Company to build training centre with state-of-the-art training laboratories
Roche announced today that it will be applying at the end of July for permission to build a new training centre at its Kaiseraugst site. The company plans to invest around 86 million Swiss francs in the centre, which will offer staff training facilities and state-of-the-art vocational training laboratories. As the new training centre will be the first office and laboratory building on the eastern side of the Kaiseraugst site, Roche will invest an additional 23 million francs in site development.
“In the past five years, headcount at Kaiseraugst has grown by 30 percent to around 1,600 employees. As a result, demand for employee training is rising,” says Matthias M. Baltisberger, Site Head at Roche Basel/Kaiseraugst. “Traditionally, we place great emphasis on providing vocational training within the company and offer around 300 young people training in 14 different occupations.”
Construction work on the centre is slated to begin in September 2013, subject to official approval. The centre should be ready for use in October 2014.
In recent years Roche has invested nearly 400 million Swiss francs in its Kaiseraugst site for the construction of a sterile manufacturing facility, a new Quality Control and Quality Assurance laboratory building, and a new logistics centre.
About the Building 229 Training Centre in Kaiseraugst
The five-story building will provide a pleasant and comfortable working environment, offering 11,900 m2 of gross surface area with numerous conference rooms and training laboratories. Architecturally, its style will be similar to existing buildings on the Kaiseraugst site.
About Roche in Kaiseraugst
One of the most modern pharmaceutical packaging and logistics centres in Europe was completed in Kaiseraugst in 1995. The Kaiseraugst site is an important hub in Roche’s global production and logistics network. The state-of-the-art centre of excellence for sterile production is also the company’s biggest packaging facility, supplying medicines to around 130 countries. Kaiseraugst plays a pivotal role in the Roche Group and currently has an employee headcount of approximately 1,600.
Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, infectious diseases, inflammation, metabolism and neuroscience. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Roche’s personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2012 Roche had over 80,000 employees worldwide and invested over 8 billion Swiss francs in R&D. The Group posted sales of 45.5 billion Swiss francs. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.